{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"condition":["Unresectable, advanced or recurrent colorectal cancer"],"disease":["Unresectable, Advanced Or Recurrent Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2614948"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"NYX study","description":"Interventions: arm A: Oral administration of TSUMURA Ninjin’yoeito 9.0 g/day in 2 or 3 divided doses before or between meals, from the day 1 of the first cycle to the last day of the 8th cycle in CapeOX + Bmab therapy.\narm B: Non-treatment of TSUMURA Ninjin’yoeito.\nPrimary outcome(s): 1. Maintenance of nutritional status (CONUT)\n2. Incidence of non-hematological adverse events >= grade 3 of CapeOX +Bmab therapy\nStudy Design: randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose","dates":{"creation":"2020-03-15"},"accession":"2614948","cross_references":{"Japan Primary Registries Network":["JPRN-jRCTs041190071"]}}